Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 9

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 9
---
 Merger or passed upon the adequacy or accuracy of this proxy statement/prospectus. Any representation to the contrary is a criminal offense. This proxy statement/prospectus is not intended to be and is not a prospectus for purposes of the Israeli Securities Law, 5728-1968, and the Israeli Securities Authority has not approved this proxy statement/prospectus. The accompanying proxy statement is dated ____, 2025, and is first being mailed to NLS shareholders on or about _____, 2025.

PRELIMINARY PROXY STATEMENT, SUBJECT TO COMPLETION NLS PHARMACEUTICS LTD.
The Circle 6
8058 Zurich, Switzerland
Tel: +41.44.512.2150 NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS
TO BE HELD ON , 2025 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich,, 2025 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle6, 8058 Zurich, Switzerland (the “Company”), is pleased to invite you to the extraordinary shareholders’ meeting of the Company. The shareholders’ meeting will be held as follows:

| Date:         |     |                                                             , 2025 |
| Doors open:   |     |                                                      3:45 pm (CET) |
| Meeting time: |     |                                                      4:00 pm (CET) |
| Place:        |     | Advokatur 107, Rorschacher Str. 107, 9000 St. Gallen, Switzerland. |

The agenda items to be voted on, the voting instructions and the appendices mentioned herein are provided below: The Board of Directors reserves the right, for important reasons in the interest of the Company, to withdraw all subsequent proposals should any agenda item be rejected by the shareholders. In this case, none of the agenda items would be put to a vote. The agenda items and proposals of the Board of Directors are as follows: 1.Advisory vote: Approval of Merger Agreement Explanation:The Company entered into a merger agreement Kadimastem Ltd. (“Kadimastem”) on November 4, 2024 (“Merger Agreement”) as announced and filed with the United States Securities and Exchange Commission on November 4 and 5, 202